Clinical trialNCT06846515CompletedPhase 3Interventional

Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-301)

SponsorArthrosi TherapeuticsEnrollment866Arthritis, GoutyGoutGout ChronicHyperuricemia

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This study will assess the serum uric acid lowering effect and safety of AR882 in gout patients at two doses compared to placebo over 12 months

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Robert Keenan, MD
Arthrosi Therapeutics, Inc.
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

83 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Arthrosi Investigative Site (620)
Birmingham, Alabama, United States
Arthrosi Investigative Site (616)
Huntsville, Alabama, United States
Arthrosi Investigative Site (680)
Peoria, Arizona, United States
Arthrosi Investigative Site (640)
Phoenix, Arizona, United States
Arthrosi Investigative Site (617)
Little Rock, Arkansas, United States
Arthrosi Investigative Site (614)
Garden Grove, California, United States
Arthrosi Investigative Site (618)
La Mesa, California, United States
Arthrosi Investigative Site (687)
La Mesa, California, United States
Arthrosi Investigative Site (655)
La Palma, California, United States
Arthrosi Investigative Site (632)
Lincoln, California, United States
Arthrosi Investigative Site (605)
Lomita, California, United States
Arthrosi Investigative Site (675)
Long Beach, California, United States
Arthrosi Investigative Site (603)
Santa Monica, California, United States
Arthrosi Investigative Site (672)
Tarzana, California, United States
Arthrosi Investigative Site (656)
Thousand Oaks, California, United States
Arthrosi Investigative Site (660)
Aurora, Colorado, United States
Arthrosi Investigative Site (669)
Colorado Springs, Colorado, United States
Arthrosi Investigative Site (612)
Fort Collins, Colorado, United States
Arthrosi Investigative Site (665)
Cooper City, Florida, United States
Arthrosi Investigative Site (613)
Jupiter, Florida, United States
Arthrosi Investigative Site (611)
Miami, Florida, United States
Arthrosi Investigative Site (644)
Miami, Florida, United States
Arthrosi Investigative Site (694)
Palmetto Bay, Florida, United States
Arthrosi Investigative Site (615)
Sanford, Florida, United States
Arthrosi Investigative Site (600)
Tampa, Florida, United States
Arthrosi Investigative Site (673)
Atlanta, Georgia, United States
Arthrosi Investigative Site (652)
Marietta, Georgia, United States
Arthrosi Investigative Site (658)
Honolulu, Hawaii, United States
Arthrosi Investigative Site (676)
Boise, Idaho, United States
Arthrosi Investigative Site (634)
Meridian, Idaho, United States
Arthrosi Investigative Site (657)
Chicago, Illinois, United States
Arthrosi Investigative Site (648)
Melrose Park, Illinois, United States
Arthrosi Investigative Site (678)
Indianapolis, Indiana, United States
Arthrosi Investigative Site (679)
Overland Park, Kansas, United States
Arthrosi Investigative Site (674)
Louisville, Kentucky, United States
Arthrosi Investigative Site (627)
Mandeville, Louisiana, United States
Arthrosi Investigative Site (650)
New Orleans, Louisiana, United States
Arthrosi Investigative Site (641)
Prairieville, Louisiana, United States
Arthrosi Investigative Site (662)
Oxon Hill, Maryland, United States
Arthrosi Investigative Site (653)
Rockville, Maryland, United States

43 more sites on the registry record.ClinicalTrials.gov ↗

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

AR882 50 mgAR882 75 mgPlacebo

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 11 Mar 2025
Primary completion: 31 Aug 2026
Completion: 18 Sept 2026
Last update posted: 28 Sept 2026
Registered enrollment: 866
Registry id: NCT06846515

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 4 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.